This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
World-Health-Organisation. Cardiovascular Diseases (cvds) World-Health-Organisation; Geneva, Switzerland: 2013.World-Health-OrganisationCardiovascular Diseases (cvds)World-Health-OrganisationGeneva, Switzerland2013Search in Google Scholar
Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239–42.1022608710.1161/01.CIR.99.17.2239AbaciAOguzhanAKahramanSEryolNKUnalSArincHEffect of diabetes mellitus on formation of coronary collateral vesselsCirculation199999223942Search in Google Scholar
Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40(3): 209–94.1289231710.1080/713609354LambeirAMDurinxCScharpéSDe MeesterIDipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IVCrit Rev Clin Lab Sci20034032099412892317Search in Google Scholar
Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226(2): 305–14.2308368110.1016/j.atherosclerosis.2012.09.012ZhongJRaoXRajagopalanSAn emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular diseaseAtherosclerosis201322623051423083681Search in Google Scholar
Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81(5): 761–7.1739272510.1038/sj.clpt.6100167HermanGASteinPPThornberryNAWagnerJADipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptinClin Pharmacol Ther2007815761717392725Search in Google Scholar
Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition bysaxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol 2012; 12: 2.2247504910.1186/1471-2210-12-2WangADorsoCKopchoLLockeGLangishRHarstadEPotency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition bysaxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitorBMC Pharmacol2012122337338022475049Search in Google Scholar
Jianqiang Z, Qiuyue C, Jixin Z, Chaohong L, Bing Z, Quan G. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. Front Immunol 2019; 10: 1050.10.3389/fimmu.2019.0105031134095JianqiangZQiuyueCJixinZChaohongLBingZQuanGDPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive DrugsFront Immunol2019101050652675131134095Open DOISearch in Google Scholar
Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223: 133.2130421710.1620/tjem.223.133OgawaSIshikiMNakoKOkamuraMSendaMMoriTSitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetesTohoku J Exp Med201122313321304217Search in Google Scholar
Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2016; 8: 26.10.1186/s13098-016-0144-627006706DuvnjakLBlaslovKDipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitusDiabetol Metab Syndr2016826480288327006706Open DOISearch in Google Scholar
Chen K, Zhuo T, Wang J, Mei Q. Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus. Metab Syndr Relat Disord 2018; 16: 336–41.10.1089/met.2018.001029912623ChenKZhuoTWangJMeiQSaxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitusMetab Syndr Relat Disord2018163364129912623Open DOISearch in Google Scholar
Hussain M, Atif MA, Ghafoor MB. Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients. Pak J Pharm Sci 2016; 29: 2385–9.28167482HussainMAtifMAGhafoorMBBeneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patientsPak J Pharm Sci20162923859Search in Google Scholar
Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29: 520–8.2115064010.1097/HJH.0b013e328341939dPachecoBPCrajoinasROCoutoGKDavelAPLessaLMRossoniLVDipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive ratsJ Hypertens201129520821150640Search in Google Scholar
Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012; 60: 833–41.10.1161/HYPERTENSIONAHA.112.19511522868389LiuLLiuJWongWTTianXYLauCWWangYXDipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanismHypertension2012608334122868389Open DOISearch in Google Scholar
Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res 2015; 38: 237–43.2558885010.1038/hr.2014.173SufiunARafiqKFujisawaYRahmanAMoriHNakanoDEffect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in ratsHypertens Res20153823743439045325588850Search in Google Scholar
Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012; 60: 467–73.10.1097/FJC.0b013e31826be20422932707MasonRPJacobRFKubantRCiszewskiACorbalanJJMalinskiTDipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive ratsJ Cardiovasc Pharmacol2012604677322932707Open DOISearch in Google Scholar
Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119–30.10.1159/000341487AlterMLOttIMvon WebskyKTsuprykovOSharkovskaYKrause-RelleKDPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathyKidney Blood Press Res2012361193023171828Open DOISearch in Google Scholar
Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013; 31: 2290–8.10.1097/HJH.0b013e3283649b4d24077249ChaykovskaLAlterMLvon WebskyKHohmannMTsuprykovOReichetzederCEffects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertensionJ Hypertens2013312290824077249Open DOISearch in Google Scholar
Pari L, Chandramohan R. Modulatory effects of naringin on hepatic key enzymes of carbohydrate metabolism in high-fat diet/low-dose streptozotocin-induced diabetes in rats. Gen Physiol Biophys 2017; 36(3): 343–52.2863561110.4149/gpb_2016055PariLChandramohanRModulatory effects of naringin on hepatic key enzymes of carbohydrate metabolism in high-fat diet/low-dose streptozotocin-induced diabetes in ratsGen Physiol Biophys20173633435228635611Search in Google Scholar
Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, Di-Petrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21(12):1288–91.10.1038/ajh.2008.30118846043FengMWhitesallSZhangYBeibelMD'AlecyLDi-PetrilloKValidation of volume-pressure recording tail-cuff blood pressure measurementsAm J Hypertens2008211212889118846043Open DOISearch in Google Scholar
Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 2015; 65: 238–49.10.1161/HYPERTENSIONAHA.114.0463125368027JacksonEKMiZTofovicSPGillespieDGEffect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependentHypertension20156523849426842825368027Open DOISearch in Google Scholar
Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab 2007; 3(10): 667.10.1038/ncpendmet063817893686LagoRMSinghPPNestoRWDiabetes and hypertensionNat Clin Pract Endocrinol Metab200731066717893686Open DOISearch in Google Scholar
Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223(2): 133–5.2130421710.1620/tjem.223.133OgawaSIshikiMNakoKOkamuraMSendaMMoriTSitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetesTohoku J Exp Med20112232133521304217Search in Google Scholar
Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes. J Korean Med Sci 2012; 27(11): 1364–70.10.3346/jkms.2012.27.11.136423166419KubotaYMiyamotoMTakagiGIkedaTKirinoki-IchikawaSTanakaKThe Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 DiabetesJ Korean Med Sci20122711136470349267223166419Open DOISearch in Google Scholar
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48(5): 592–8.1835399610.1177/0091270008316885MistryGCMaesALLasseterKCDaviesMJGottesdienerKMWagnerJAEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertensionJ Clin Pharmacol2008485592818353996Search in Google Scholar
Gouni-Berthold I, Hanssen R, Ravarani L, Berthold HK. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23(31): 4573–82.28911306Gouni-BertholdIHanssenRRavaraniLBertholdHKManagement of Blood Pressure and Heart Rate in Patients with Diabetes MellitusCurr Pharm Des2017233145738210.2174/138161282366617060908443628911306Search in Google Scholar
Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56: 728–33.10.1161/HYPERTENSIONAHA.110.15655420679179MarneyAKunchakarraSByrneLBrownNJInteractive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humansHypertension20105672833330504720679179Open DOISearch in Google Scholar
Monami M, Vitale V, Ambrosio VL, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 2012; 29(9): 736–46.2292316110.1007/s12325-012-0045-5MonamiMVitaleVAmbrosioVLEffects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trialsAdv Ther20122997364622923161Search in Google Scholar
Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173–7.10.1016/j.regpep.2004.08.02415582729NystromTGononATSjoholmAPernowJGlucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanismRegul Pept2005125173715582729Open DOISearch in Google Scholar
Shah Z, Pineda C, Kampfrath T, Maiseyu A, Ying Z, Racoma I, et al. Acute DPP-4 inhibition modulates vacular tone through GLP-1 independent pathways. Vascular Pharmacol 2011; 55(1–3): 111–7.ShahZPinedaCKampfrathTMaiseyuAYingZRacomaIAcute DPP-4 inhibition modulates vacular tone through GLP-1 independent pathwaysVascular Pharmacol2011551–3111710.1016/j.vph.2011.03.001484595121397040Search in Google Scholar
da Silva Júnior WS, Souza M, Nogueira Neto JF, Bouskela E, Kraemer-Aguiar LG. Constitutive DPP4 activity, inflammation, and microvascular reactivity in subjects with excess body weight and without diabetes. Microvasc Res 2018; 120: 94–9.3007120310.1016/j.mvr.2018.07.005da Silva JúniorWSSouzaMNogueira NetoJFBouskelaEKraemer-AguiarLGConstitutive DPP4 activity, inflammation, and microvascular reactivity in subjects with excess body weight and without diabetesMicrovasc Res201812094930071203Search in Google Scholar
Schon E, Demuth HU, Eichmann E, Horst HJ, Korner IJ, Kopp J, et al. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989; 29: 127–32.SchonEDemuthHUEichmannEHorstHJKornerIJKoppJDipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IVScand J Immunol1989291273210.1111/j.1365-3083.1989.tb01108.x2564215Search in Google Scholar
Avogaro A, Giorda C, Maggini M, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241–7.10.2337/dc06-255817290034AvogaroAGiordaCMagginiMIncidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic locationDiabetes Care2007301241717290034Open DOISearch in Google Scholar
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91.10.1056/NEJMoa070624518256393GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med20083585809118256393Open DOISearch in Google Scholar
Derosa G, Tritto I, Romano D, D'Angelo A, Catena G, Maffioli P. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. J Clin Pharmacol 2019 doi: 10.1002/jcph.1431. [Epub ahead of print].31131461DerosaGTrittoIRomanoDD'AngeloACatenaGMaffioliPEffects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of TherapyJ Clin Pharmacol201910.1002/jcph.1431[Epub ahead of print]31131461Open DOISearch in Google Scholar
Addison, D, and Aguilar, D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep 2011; 13(2): 115–22.2117061110.1007/s11883-010-0153-0AddisonDAguilarDDiabetes and cardiovascular disease: the potential benefit of incretin-based therapiesCurr Atheroscler Rep201113211522306386021170611Search in Google Scholar
Saad, M.I., Kamel, M.A., and Hanafi, M.Y. Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD/STZ diabetic rats. Biochem Res Int 2015: 138134.25838947SaadM.I.KamelM.A.HanafiM.Y.Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD/STZ diabetic ratsBiochem Res Int201513813410.1155/2015/138134436995025838947Search in Google Scholar
Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018; 38(1): 56–63.2942749210.1111/liv.13676IssaDPatelVSanyalAJFuture therapy for non-alcoholic fatty liver diseaseLiver Int2018381566329427492Search in Google Scholar
Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1106–7.10.1172/JCI1103357287903WasadaTMcCorkleKHarrisVKawaiKHowardBUngerRHEffect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogsJ Clin Invest19816811067Open DOISearch in Google Scholar
Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 2007; 282: 8557–67.10.1074/jbc.M60908820017244606KimSJNianCMcIntoshCHActivation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascadeJ Biol Chem200728285576717244606Open DOISearch in Google Scholar
Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452–8.10.1007/s00125-005-0126-y16447057MeierJJGethmannAGötzeOGallwitzBHolstJJSchmidtWEGlucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humansDiabetologia200649452816447057Open DOISearch in Google Scholar
Masuda D, Kobayashi T, Sairyou M, Hanada H, Ohama T, Koseki M, et al. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial). J Atheroscler Thromb 2018; 25(6): 512–20.10.5551/jat.4134329199201MasudaDKobayashiTSairyouMHanadaHOhamaTKosekiMEffects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)J Atheroscler Thromb201825651220600523129199201Open DOISearch in Google Scholar
